The efficacy of tolvaptan in a population with congestive heart failure and chronic kidney disease: A multicenter, randomized, open label, blind endpoint study (AQUAKID-Study)

Trial Profile

The efficacy of tolvaptan in a population with congestive heart failure and chronic kidney disease: A multicenter, randomized, open label, blind endpoint study (AQUAKID-Study)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 May 2016

At a glance

  • Drugs Tolvaptan (Primary) ; Furosemide
  • Indications Heart failure; Kidney disorders
  • Focus Therapeutic Use
  • Acronyms AQUAKID
  • Most Recent Events

    • 18 May 2016 Last checked against University Hospital Medical Information Network - Japan
    • 13 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top